BioCangen Inc. focuses on the development of novel methylation-based products for early cancer detection and therapeutic response prediction. At BioCangen, our mission is committed to advancing early cancer detection and prediction of individualized therapeutics to the highest levels of accuracy and performance, while simultaneously stressing simplicity and cost efficiency advantages.

With a proprietary technology called the Ultra-Sensitive Gene Methylation Amplification Technology (USGMAT), BioCangen has developed a highly sensitive and specific non-invasive test for detecting early-stage cancer, and is developing the new class of tests for predicting cancer therapy response.